Novel formulations of taxanes: a review. Old wine in a new bottle? (Q34563540)

3 August 2017

1 reference

title

Novel formulations of taxanes: a review. Old wine in a new bottle? (English)

1 reference

3 August 2017

0 references

K L Hennenfent

1

1 reference

3 August 2017

R Govindan

series ordinal

2

1 reference

3 August 2017

publication date

19 December 2005

1 reference

3 August 2017

1 reference

3 August 2017

volume

17

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

735-749

1 reference

Promotion of microtubule assembly in vitro by taxol

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Risks and benefits of taxanes in breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Hypersensitivity reactions from taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Methods for preventing reactions secondary to Cremophor EL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Role of formulation vehicles in taxane pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Is Cremophor EL, solvent for paclitaxel, cytotoxic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Influence of n-3 fatty acids on the growth of human breast cancer cellsin vitro: Relationship to peroxides and Vitamin-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Progress in the development of alternative pharmaceutical formulations of taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Poly(L-glutamic acid)--anticancer drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Preclinical antitumor activity of two novel taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ100

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDJ100

1 reference

3 August 2017

1 reference